Rare cancer patients in England are set to be matched to clinical trials through the NHS App, as ministers roll out a National Cancer Plan alongside the Rare Cancers Bill now before Parliament. The feature integrates the Be Part of Research service, which has already helped more than 100,000 people join around 160 studies, bringing trial discovery into the same place many already manage care.

Initially, patients will be able to search a live database and request contact from research teams. Over time, opt‑in notifications will flag studies that may fit a patient’s profile, shifting recruitment away from chance referrals towards a more systematic, consent‑led process. For conditions where time to enrol often determines options, this is a material upgrade.

Policy is being paired with funding. Since July 2024, brain cancer research has received an additional £32.3 million, with a further £3 million committed to co‑fund Cancer Research UK’s Brain Tumour Centres of Excellence. The money is aimed at precision medicine, better‑designed trials and developing future leaders in neuro‑oncology.

Delivery is being reorganised. A new national lead for rare cancers and a National Institute for Health and Care Research speciality lead will coordinate pathways and referrals. The objective is larger, faster and more reliable studies, supported by a single route for industry investment rather than fragmented site‑by‑site arrangements that slow timelines.

A Cancer Clinical Trials Accelerator, to be hosted through the NIHR Industry Hub, is planned to standardise and speed set‑up. For sponsors and CROs, a central accelerator should mean quicker contracting, earlier first‑patient‑in and clearer accountability on milestones. If executed well, the UK becomes a more attractive venue for complex, small‑population oncology trials.

We see three near‑term business effects. First, digital pre‑screening inside the NHS App should lift awareness and compress recruitment costs. Second, automated patient contact could improve enrolment in indications where cohorts are scarce. Third, a single pathway and clearer governance should reduce administrative drift that routinely turns weeks into quarters.

For investors, this is a measured but meaningful signal. Precision oncology start‑ups, trial‑tech vendors and data‑enabled SMEs may find a shorter route to proof‑of‑concept, with public funding de‑risking early execution. The combination of government support, CRUK partnership and an industry‑facing hub points to co‑investment in delivery, not just discovery.

There are caveats. The Rare Cancers Bill is still progressing through Parliament, and the NHS must manage workforce and IT constraints. Digital matching only works if consent, data quality and inclusion are handled properly. People without reliable smartphone access will need parallel, face‑to‑face routes to keep equity at the centre of recruitment.

Real‑world experience shows the potential. An NIHR‑funded glioblastoma study enabled surgeons to remove more tumour tissue while preserving brain function, extending time with family for one participant who had been told to expect only months. Wearable tumour‑treating field devices are then helping patients manage their condition between treatments.

The ambition is explicit: by 2035, be among Europe’s leaders on survival for 14 less common and deadlier cancers, including brain cancer. With more than 10,000 brain tumour diagnoses annually in the UK and outcomes lagging the progress seen in other cancers, scaling the trial pipeline is one of the few levers that can shift results.

For biotech boards planning UK studies, the practical work now is to align feasibility with App‑based pre‑screening, ensure data capture flows into NIHR systems, and design patient‑friendly protocols that support opt‑in notifications. Cash runway models should be refreshed if activation and enrolment timelines shorten under the accelerator.

What matters next is execution and transparency. The Accelerator and Industry Hub should publish service levels, time‑to‑contract targets and enrolment data by region and demographic. If those numbers are visible and improving, capital will follow-and the promise on rare cancers will move from policy statement to measurable performance.